Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors, approved for the treatment of type 2 diabetes in adults, function via an insulin-independent mechanism for improving blood glucose levels (44). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.